{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:39:42Z","timestamp":1789011582758,"version":"build-2803163510"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2015,7,21]],"date-time":"2015-07-21T00:00:00Z","timestamp":1437436800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s00277-015-2447-3","type":"journal-article","created":{"date-parts":[[2015,7,20]],"date-time":"2015-07-20T03:20:29Z","timestamp":1437362429000},"page":"1441-1450","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":106,"title":["Antiviral prophylaxis in patients with solid tumours and haematological malignancies\u2014update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)"],"prefix":"10.1007","volume":"94","author":[{"given":"Michael","family":"Sandherr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Hentrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"von Lilienfeld-Toal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gero","family":"Massenkeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Penack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Biehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver A.","family":"Cornely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,21]]},"reference":[{"key":"2447_CR1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2174\/187152611794407773","volume":"11","author":"M Angarone","year":"2011","unstructured":"Angarone M (2011) Epidemiology and prevention of viral infections in patients with hematologic malignancies. Infect Disord Drug Targets 11:27\u201333","journal-title":"Infect Disord Drug Targets"},{"key":"2447_CR2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1473-3099(09)70175-6","volume":"9","author":"KM Kunisaki","year":"2009","unstructured":"Kunisaki KM, Janoff EN (2009) Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 9:493\u2013504","journal-title":"Lancet Infect Dis"},{"key":"2447_CR3","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1093\/annonc\/mdq254","volume":"21","author":"LA Hajjar","year":"2010","unstructured":"Hajjar LA, Mauad T, Galas FR et al (2010) Severe novel influenza A (H1N1) infection in cancer patients. Ann Onco 21:2333\u20132341","journal-title":"Ann Onco"},{"key":"2447_CR4","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/annonc\/mdj132","volume":"17","author":"M Sandherr","year":"2006","unstructured":"Sandherr M, Einsele H, Hebart H et al (2006) Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Ann Oncol 17:1051\u20131059","journal-title":"Ann Oncol"},{"key":"2447_CR5","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.6004\/jnccn.2012.0146","volume":"10","author":"LR Baden","year":"2012","unstructured":"Baden LR, Bensinger W, Angarone M et al (2012) Prevention and treatment of cancer-related infections. J Natl Compr Cancer Netw 10:1412\u20131445","journal-title":"J Natl Compr Cancer Netw"},{"key":"2447_CR6","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1200\/JCO.2012.45.8661","volume":"31","author":"CR Flowers","year":"2013","unstructured":"Flowers CR, Seidenfeld J, Bow EJ et al (2013) Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol Off J Am Soc Clin Oncol 31:794\u2013810","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2447_CR7","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1086\/319366","volume":"32","author":"MA Kish","year":"2001","unstructured":"Kish MA (2001) Guide to development of practice guidelines. Clin Infect Dis 32:851\u2013854","journal-title":"Clin Infect Dis"},{"key":"2447_CR8","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000334739","volume":"82","author":"ST Kim","year":"2012","unstructured":"Kim ST, Park KH, Oh SC et al (2012) Varicella zoster virus infection during chemotherapy in solid cancer patients. Oncology 82:126\u2013130","journal-title":"Oncology"},{"key":"2447_CR9","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1002\/cncr.11353","volume":"97","author":"KL Hicks","year":"2003","unstructured":"Hicks KL, Chemaly RF, Kontoyiannis DP (2003) Common community respiratory viruses in patients with cancer: more than just \u201ccommon colds\u201d. Cancer 97:2576\u20132587","journal-title":"Cancer"},{"key":"2447_CR10","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1182\/blood-2003-05-1425","volume":"103","author":"EJ Anaissie","year":"2004","unstructured":"Anaissie EJ, Mahfouz TH, Aslan T et al (2004) The natural history of respiratory syncytial virus infection in cancer and transplant patients: implications for management. Blood 103:1611\u20131617","journal-title":"Blood"},{"key":"2447_CR11","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/S1470-2045(08)70255-9","volume":"9","author":"S Vento","year":"2008","unstructured":"Vento S, Cainelli F, Temesgen Z (2008) Lung infections after cancer chemotherapy. Lancet Oncol 9:982\u2013992","journal-title":"Lancet Oncol"},{"key":"2447_CR12","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1093\/annonc\/mdq351","volume":"21","author":"D Francisci","year":"2010","unstructured":"Francisci D, Labianca R, Roila F (2010) Prevention and treatment of pandemic influenza in cancer patients. Ann Oncol 21:2301\u20132303","journal-title":"Ann Oncol"},{"key":"2447_CR13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2174\/187152611794407818","volume":"11","author":"MG Ison","year":"2011","unstructured":"Ison MG (2011) Epidemiology, prevention, and management of influenza in patients with hematologic malignancy. Infect Disord Drug Targets 11:34\u201339","journal-title":"Infect Disord Drug Targets"},{"key":"2447_CR14","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/annonc\/mdq728","volume":"22","author":"A Meerveld-Eggink","year":"2011","unstructured":"Meerveld-Eggink A, de Weerdt O, van der Velden AM et al (2011) Response to influenza virus vaccination during chemotherapy in patients with breast cancer. Ann Oncol 22:2031\u20132035","journal-title":"Ann Oncol"},{"key":"2447_CR15","first-page":"CD008983","volume":"10","author":"N Eliakim-Raz","year":"2013","unstructured":"Eliakim-Raz N, Vinograd I, Zalmanovici Trestioreanu A, Leibovici L, Paul M (2013) Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database Syst Rev 10:CD008983","journal-title":"Cochrane Database Syst Rev"},{"key":"2447_CR16","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0308-2261(21)00449-5","volume":"13","author":"R Saral","year":"1984","unstructured":"Saral R, Burns WH, Prentice HG (1984) Herpes virus infections: clinical manifestations and therapeutic strategies in immunocompromised patients. Clin Haematol 13:645\u2013660","journal-title":"Clin Haematol"},{"key":"2447_CR17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/bjc.1984.138","volume":"50","author":"H Anderson","year":"1984","unstructured":"Anderson H, Scarffe JH, Sutton RN, Hickmott E, Brigden D, Burke C (1984) Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind, placebo controlled trial. Br J Cancer 50:45\u201349","journal-title":"Br J Cancer"},{"key":"2447_CR18","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1200\/JCO.1997.15.6.2269","volume":"15","author":"OJ Bergmann","year":"1997","unstructured":"Bergmann OJ, Mogensen SC, Ellermann-Eriksen S, Ellegaard J (1997) Acyclovir prophylaxis and fever during remission-induction therapy of patients with acute myeloid leukemia: a randomized, double-blind, placebo-controlled trial. J Clin Oncol Off J Am Soc Clin Oncol 15:2269\u20132274","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2447_CR19","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1016\/j.ejca.2009.08.010","volume":"45","author":"D Yahav","year":"2009","unstructured":"Yahav D, Gafter-Gvili A, Muchtar E et al (2009) Antiviral prophylaxis in haematological patients: systematic review and meta-analysis. Eur J Cancer 45:3131\u20133148","journal-title":"Eur J Cancer"},{"key":"2447_CR20","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/bmt.2008.386","volume":"43","author":"J Styczynski","year":"2009","unstructured":"Styczynski J, Reusser P, Einsele H et al (2009) Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 43:757\u2013770","journal-title":"Bone Marrow Transplant"},{"key":"2447_CR21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/tid.12054","volume":"15","author":"D Engelhard","year":"2013","unstructured":"Engelhard D, Mohty B, de la Camara R, Cordonnier C, Ljungman P (2013) European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN. Transpl Infect Dis 15:219\u2013232","journal-title":"Transpl Infect Dis"},{"key":"2447_CR22","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0","volume":"62","author":"W Yeo","year":"2000","unstructured":"Yeo W, Chan PK, Zhong S et al (2000) Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62:299\u2013307","journal-title":"J Med Virol"},{"key":"2447_CR23","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/sj.bjc.6601699","volume":"90","author":"W Yeo","year":"2004","unstructured":"Yeo W, Zee B, Zhong S et al (2004) Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 90:1306\u20131311","journal-title":"Br J Cancer"},{"key":"2447_CR24","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1177\/1756283X12450245","volume":"5","author":"YW Huang","year":"2012","unstructured":"Huang YW, Chung RT (2012) Management of hepatitis B reactivation in patients receiving cancer chemotherapy. Ther Adv Gastroenterol 5:359\u2013370","journal-title":"Ther Adv Gastroenterol"},{"key":"2447_CR25","doi-asserted-by":"crossref","first-page":"e0126037","DOI":"10.1371\/journal.pone.0126037","volume":"10","author":"CY Chen","year":"2015","unstructured":"Chen CY, Huang SY, Cheng A et al (2015) High risk of hepatitis B reactivation among patients with acute myeloid leukemia. PLoS One 10:e0126037","journal-title":"PLoS One"},{"key":"2447_CR26","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/jmv.10430","volume":"70","author":"W Yeo","year":"2003","unstructured":"Yeo W, Chan PK, Hui P et al (2003) Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 70:553\u2013561","journal-title":"J Med Virol"},{"key":"2447_CR27","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/bjc.2011.4","volume":"104","author":"J Yun","year":"2011","unstructured":"Yun J, Kim KH, Kang ES et al (2011) Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy. Br J Cancer 104:559\u2013563","journal-title":"Br J Cancer"},{"key":"2447_CR28","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1073\/pnas.83.6.1627","volume":"83","author":"R Tur-Kaspa","year":"1986","unstructured":"Tur-Kaspa R, Burk RD, Shaul Y, Shafritz DA (1986) Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci U S A 83:1627\u20131631","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2447_CR29","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/jhep.2003.50220","volume":"37","author":"AL Cheng","year":"2003","unstructured":"Cheng AL, Hsiung CA, Su IJ et al (2003) Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 37:1320\u20131328","journal-title":"Hepatology"},{"key":"2447_CR30","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","volume":"148","author":"KR Reddy","year":"2015","unstructured":"Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT (2015) American Gastroenterological Association I. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 148:215\u2013219, quiz e16-7","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"2447_CR31","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/S1590-8658(10)60692-5","volume":"43","author":"C Marinone","year":"2011","unstructured":"Marinone C, Mestriner M (2011) HBV disease: HBsAg carrier and occult B infection reactivation in haematological setting. Dig Liver Dis 43(Suppl 1):S49\u2013S56","journal-title":"Dig Liver Dis"},{"key":"2447_CR32","doi-asserted-by":"crossref","unstructured":"O\u2019Brien SN, Blijlevens NM, Mahfouz TH, Anaissie EJ (2003) Infections in patients with hematological cancer: recent developments. Hematology 438\u201372","DOI":"10.1182\/asheducation-2003.1.438"},{"key":"2447_CR33","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/00001432-200108000-00002","volume":"14","author":"G Samonis","year":"2001","unstructured":"Samonis G, Kontoyiannis DP (2001) Infectious complications of purine analog therapy. Curr Opin Infect Dis 14:409\u2013413","journal-title":"Curr Opin Infect Dis"},{"key":"2447_CR34","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-129-7-199810010-00010","volume":"129","author":"EJ Anaissie","year":"1998","unstructured":"Anaissie EJ, Kontoyiannis DP, O\u2019Brien S et al (1998) Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 129:559\u2013566","journal-title":"Ann Intern Med"},{"key":"2447_CR35","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2165\/11201110-000000000-00000","volume":"70","author":"GM Keating","year":"2010","unstructured":"Keating GM (2010) Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 70:1445\u20131476","journal-title":"Drugs"},{"key":"2447_CR36","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1586\/14737140.6.8.1175","volume":"6","author":"G Held","year":"2006","unstructured":"Held G, Poschel V, Pfreundschuh M (2006) Rituximab for the treatment of diffuse large B-cell lymphomas. Expert Rev Anticancer Ther 6:1175\u20131186","journal-title":"Expert Rev Anticancer Ther"},{"key":"2447_CR37","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1634\/theoncologist.2010-0182","volume":"16","author":"C Leung","year":"2011","unstructured":"Leung C, Tsoi E, Burns G, Sievert W (2011) An argument for the universal prophylaxis of hepatitis B infection in patients receiving rituximab: a 7-year institutional experience of hepatitis screening. Oncologist 16:579\u2013584","journal-title":"Oncologist"},{"key":"2447_CR38","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2217\/imt.09.59","volume":"1","author":"Y Tsutsumi","year":"2009","unstructured":"Tsutsumi Y, Yamamoto Y, Tanaka J, Asaka M, Imamura M, Masauzi N (2009) Prevention of hepatitis B virus reactivation under rituximab therapy. Immunotherapy 1:1053\u20131061","journal-title":"Immunotherapy"},{"key":"2447_CR39","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1478-3231.2010.02332.x","volume":"31","author":"J Mendez-Navarro","year":"2011","unstructured":"Mendez-Navarro J, Corey KE, Zheng H et al (2011) Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy. Liver Int 31:330\u2013339","journal-title":"Liver Int"},{"key":"2447_CR40","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/annonc\/mdq583","volume":"22","author":"AM Evens","year":"2011","unstructured":"Evens AM, Jovanovic BD, Su YC et al (2011) Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 22:1170\u20131180","journal-title":"Ann Oncol"},{"key":"2447_CR41","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(09)70161-5","volume":"10","author":"KR Carson","year":"2009","unstructured":"Carson KR, Focosi D, Major EO et al (2009) Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 10:816\u2013824","journal-title":"Lancet Oncol"},{"key":"2447_CR42","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.3109\/10428194.2012.742524","volume":"54","author":"D Villa","year":"2013","unstructured":"Villa D, Gubbay J, Sutherland DR et al (2013) Evaluation of 2009 pandemic H1N1 influenza vaccination in adults with lymphoid malignancies receiving chemotherapy or following autologous stem cell transplant. Leuk Lymphoma 54:1387\u20131395","journal-title":"Leuk Lymphoma"},{"key":"2447_CR43","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.6004\/jnccn.2012.0147","volume":"10","author":"NC Issa","year":"2012","unstructured":"Issa NC, Baden LR (2012) Current issues in vaccines for adult patients with hematologic malignancies. J Natl Compr Cancer Netw 10:1447\u20131454, quiz 54","journal-title":"J Natl Compr Cancer Netw"},{"key":"2447_CR44","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1586\/14787210.2014.870473","volume":"12","author":"JA Buensalido","year":"2014","unstructured":"Buensalido JA, Chandrasekar PH (2014) Prophylaxis against hepatitis B reactivation among patients with lymphoma receiving rituximab. Expert Rev Anti-Infect Ther 12:151\u2013154","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"2447_CR45","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","volume":"57","author":"European Association For The Study Of The L","year":"2012","unstructured":"European Association For The Study Of The L (2012) EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 57:167\u2013185","journal-title":"J Hepatol"},{"key":"2447_CR46","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2010.30.0673","volume":"28","author":"AS Artz","year":"2010","unstructured":"Artz AS, Somerfield MR, Feld JJ et al (2010) American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol Off J Am Soc Clin Oncol 28:3199\u20133202","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"Suppl 6","key":"2447_CR47","doi-asserted-by":"crossref","first-page":"vi59","DOI":"10.1093\/annonc\/mdr388","volume":"22","author":"M Dreyling","year":"2011","unstructured":"Dreyling M, Ghielmini M, Marcus R, Salles G, Vitolo U, Group EGW (2011) Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl 6):vi59\u2013vi63","journal-title":"Ann Oncol"},{"key":"2447_CR48","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2141.2011.08969.x","volume":"156","author":"C McNamara","year":"2012","unstructured":"McNamara C, Davies J, Dyer M et al (2012) Guidelines on the investigation and management of follicular lymphoma. Br J Haematol 156:446\u2013467","journal-title":"Br J Haematol"},{"key":"2447_CR49","doi-asserted-by":"crossref","first-page":"484","DOI":"10.6004\/jnccn.2011.0046","volume":"9","author":"AD Zelenetz","year":"2011","unstructured":"Zelenetz AD, Abramson JS, Advani RH et al (2011) Non-Hodgkin\u2019s lymphomas. J Natl Compr Cancer Netw 9:484\u2013560","journal-title":"J Natl Compr Cancer Netw"},{"key":"2447_CR50","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1136\/ard.2010.143420","volume":"70","author":"MH Buch","year":"2011","unstructured":"Buch MH, Aletaha D, Emery P, Smolen JS (2011) Reporting of long-term extension studies: lack of consistency calls for consensus. Ann Rheum Dis 70:886\u2013890","journal-title":"Ann Rheum Dis"},{"key":"2447_CR51","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1002\/hep.22882","volume":"49","author":"CM Weinbaum","year":"2009","unstructured":"Weinbaum CM, Mast EE, Ward JW (2009) Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. Hepatology 49:S35\u2013S44","journal-title":"Hepatology"},{"key":"2447_CR52","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/ard.2010.144998","volume":"70","author":"MH Buch","year":"2011","unstructured":"Buch MH, Smolen JS, Betteridge N et al (2011) Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 70:909\u2013920","journal-title":"Ann Rheum Dis"},{"key":"2447_CR53","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2011.40.7510","volume":"30","author":"U Zurawska","year":"2012","unstructured":"Zurawska U, Hicks LK, Woo G et al (2012) Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. J Clin Oncol Off J Am Soc Clin Oncol 30:3167\u20133173","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2447_CR54","author":"A Kumar","year":"2014","unstructured":"Kumar A, Younes A (2014) Role of CD30 targeting in malignant lymphoma. Curr Treat Options in Oncol. doi: 10.1007\/s11864-014-0275-7","journal-title":"Curr Treat Options in Oncol"},{"key":"2447_CR55","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10354-004-0067-y","volume":"154","author":"OA Cornely","year":"2004","unstructured":"Cornely OA, Ullmann AJ, Karthaus M (2004) Opportunistic infections after treatment with monoclonal antibodies. Wien Med Wochenschr 154:209\u2013217","journal-title":"Wien Med Wochenschr"},{"key":"2447_CR56","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.2013.099358","volume":"99","author":"M Engelhardt","year":"2014","unstructured":"Engelhardt M, Terpos E, Kleber M et al (2014) European myeloma network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica 99:232\u2013242","journal-title":"Haematologica"},{"key":"2447_CR57","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1200\/JCO.2007.14.9641","volume":"26","author":"A Chanan-Khan","year":"2008","unstructured":"Chanan-Khan A, Sonneveld P, Schuster MW et al (2008) Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 26:4784\u20134790","journal-title":"J Clin Oncol"},{"key":"2447_CR58","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.suponc.2011.10.006","volume":"10","author":"A Swaika","year":"2012","unstructured":"Swaika A, Paulus A, Miller KC et al (2012) Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients. J Support Oncol 10:155\u2013159","journal-title":"J Support Oncol"},{"key":"2447_CR59","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/jjco\/hyr063","volume":"41","author":"T Aoki","year":"2011","unstructured":"Aoki T, Nishiyama T, Imahashi N, Kitamura K (2011) Efficacy of continuous, daily, oral, ultra-low-dose 200 mg acyclovir to prevent herpes zoster events among bortezomib-treated patients: a report from retrospective study. Jpn J Clin Oncol 41:876\u2013881","journal-title":"Jpn J Clin Oncol"},{"key":"2447_CR60","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3816\/CLM.2009.n.036","volume":"9","author":"L Pour","year":"2009","unstructured":"Pour L, Adam Z, Buresova L et al (2009) Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib. Clin Lymphoma Myeloma 9:151\u2013153","journal-title":"Clin Lymphoma Myeloma"},{"key":"2447_CR61","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/cncr.24006","volume":"115","author":"E Vickrey","year":"2009","unstructured":"Vickrey E, Allen S, Mehta J, Singhal S (2009) Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer 115:229\u2013232","journal-title":"Cancer"},{"key":"2447_CR62","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1182\/blood-2009-11-255455","volume":"115","author":"C Casper","year":"2010","unstructured":"Casper C, Englund J, Boeckh M (2010) How I treat influenza in patients with hematologic malignancies. Blood 115:1331\u20131342","journal-title":"Blood"},{"key":"2447_CR63","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1399-3062.2011.00655.x","volume":"13","author":"JE Rogers","year":"2011","unstructured":"Rogers JE, Cumpston A, Newton M, Craig M (2011) Onset and complications of varicella zoster reactivation in the autologous hematopoietic cell transplant population. Transpl Infect Dis 13:480\u2013484","journal-title":"Transpl Infect Dis"},{"key":"2447_CR64","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1086\/318491","volume":"32","author":"T Barton","year":"2001","unstructured":"Barton T, Collis T, Stadtmauer E, Schuster M (2001) Infectious complications the year after autologous bone marrow transplantation or peripheral stem cell transplantation for treatment of breast cancer. Clin Infect Dis 32:391\u2013395","journal-title":"Clin Infect Dis"},{"key":"2447_CR65","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1182\/blood.V94.12.4029","volume":"94","author":"LA Holmberg","year":"1999","unstructured":"Holmberg LA, Boeckh M, Hooper H et al (1999) Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood 94:4029\u20134035","journal-title":"Blood"},{"key":"2447_CR66","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s00277-012-1456-8","volume":"91","author":"F Weissinger","year":"2012","unstructured":"Weissinger F, Auner HW, Bertz H et al (2012) Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation\u2014Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 91:1161\u20131174","journal-title":"Ann Hematol"},{"key":"2447_CR67","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2162-3619-3-4","volume":"3","author":"A Novero","year":"2014","unstructured":"Novero A, Ravella PM, Chen Y, Dous G, Liu D (2014) Ibrutinib for B cell malignancies. Exp Hematol Oncol 3:4","journal-title":"Exp Hematol Oncol"},{"key":"2447_CR68","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3109\/08830185.2013.786711","volume":"32","author":"T Robak","year":"2013","unstructured":"Robak T, Robak P (2013) BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies. Int Rev Immunol 32:358\u2013376","journal-title":"Int Rev Immunol"},{"key":"2447_CR69","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10549-013-2681-0","volume":"141","author":"E Teplinsky","year":"2013","unstructured":"Teplinsky E, Cheung D, Weisberg I et al (2013) Fatal hepatitis B reactivation due to everolimus in metastatic breast cancer: case report and review of literature. Breast Cancer Res Treat 141:167\u2013172","journal-title":"Breast Cancer Res Treat"},{"key":"2447_CR70","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","volume":"122","author":"F Cervantes","year":"2013","unstructured":"Cervantes F, Vannucchi AM, Kiladjian JJ et al (2013) Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 122:4047\u20134053","journal-title":"Blood"},{"key":"2447_CR71","doi-asserted-by":"crossref","unstructured":"Wang ML, Blum KA, Martin P, et al (2015) Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood","DOI":"10.1182\/blood-2015-03-635326"},{"key":"2447_CR72","doi-asserted-by":"crossref","unstructured":"D\u2019Aniello C, Maruzzo M, Basso U (2013) Prevention of hepatitis B virus reactivation with lamivudine in a patient with advanced renal cell carcinoma treated with everolimus. Am J Ther","DOI":"10.1097\/MJT.0000000000000005"},{"key":"2447_CR73","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/978-3-642-15742-4_45","volume-title":"Pulmonary involvment in patients with haematological malignancies","author":"M Sandherr","year":"2011","unstructured":"Sandherr M (2011) Antiviral agents in patients with haematological malignancies and acute respiratory failure. In: Azoulay E (ed) Pulmonary involvment in patients with haematological malignancies. Springer Verlag, Berlin, pp 589\u2013595"},{"key":"2447_CR74","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/sj.bmt.1703817","volume":"31","author":"D Eisen","year":"2003","unstructured":"Eisen D, Essell J, Broun ER, Sigmund D, DeVoe M (2003) Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy. Bone Marrow Transplant 31:51\u201355","journal-title":"Bone Marrow Transplant"},{"key":"2447_CR75","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1345\/aph.1A434","volume":"36","author":"DI Warkentin","year":"2002","unstructured":"Warkentin DI, Epstein JB, Campbell LM et al (2002) Valacyclovir versus acyclovir for HSV prophylaxisin neutropenic patients. Ann Pharmacother 36:1525\u20131531","journal-title":"Ann Pharmacother"},{"key":"2447_CR76","unstructured":"RKI Sa. Empfehlungen der St\u00e4ndigen Impfkommission (STIKO) am Robert Koch-Institut. Epidemiologisches Bulletin 2013; Nr. 34:313-44"},{"key":"2447_CR77","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1093\/annonc\/mdu114","volume":"25","author":"P Pedrazzoli","year":"2014","unstructured":"Pedrazzoli P, Baldanti F, Donatelli I et al (2014) Vaccination for seasonal influenza in patients with cancer: recommendations of the Italian Society of Medical Oncology (AIOM). Ann Oncol 25:1243\u20131247","journal-title":"Ann Oncol"},{"key":"2447_CR78","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1385\/MO:19:2:71","volume":"19","author":"T Nordoy","year":"2002","unstructured":"Nordoy T, Aaberge IS, Husebekk A et al (2002) Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae. Med Oncol 19:71\u201378","journal-title":"Med Oncol"},{"key":"2447_CR79","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1200\/JCO.2009.26.6908","volume":"28","author":"DA Pollyea","year":"2010","unstructured":"Pollyea DA, Brown JM, Horning SJ (2010) Utility of influenza vaccination for oncology patients. J Clin Oncol 28:2481\u20132490","journal-title":"J Clin Oncol"},{"key":"2447_CR80","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3121\/cmr.3.4.214","volume":"3","author":"JJ Mazza","year":"2005","unstructured":"Mazza JJ, Yale SH, Arrowood JR et al (2005) Efficacy of the influenza vaccine in patients with malignant lymphoma. Clin Med Res 3:214\u2013220","journal-title":"Clin Med Res"},{"key":"2447_CR81","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/annonc\/mdr141","volume":"23","author":"B Rousseau","year":"2012","unstructured":"Rousseau B, Loulergue P, Mir O et al (2012) Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and\/or targeted therapy: the VACANCE study. Ann Oncol 23:450\u2013457","journal-title":"Ann Oncol"},{"key":"2447_CR82","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1365-2141.2006.06465.x","volume":"136","author":"G Lalazar","year":"2007","unstructured":"Lalazar G, Rund D, Shouval D (2007) Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 136:699\u2013712","journal-title":"Br J Haematol"},{"key":"2447_CR83","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1007\/s00520-012-1576-7","volume":"20","author":"JP Hwang","year":"2012","unstructured":"Hwang JP, Vierling JM, Zelenetz AD, Lackey SC, Loomba R (2012) Hepatitis B virus management to prevent reactivation after chemotherapy: a review. Support Care Cancer 20:2999\u20133008","journal-title":"Support Care Cancer"},{"key":"2447_CR84","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1200\/JCO.2014.56.7081","volume":"32","author":"WK Seto","year":"2014","unstructured":"Seto WK, Chan TS, Hwang YY et al (2014) Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol 32:3736\u20133743","journal-title":"J Clin Oncol"},{"key":"2447_CR85","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1038\/bjc.2013.225","volume":"108","author":"WH Ling","year":"2013","unstructured":"Ling WH, Soe PP, Pang AS, Lee SC (2013) Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours. Br J Cancer 108:1931\u20131935","journal-title":"Br J Cancer"},{"key":"2447_CR86","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","volume":"27","author":"W Yeo","year":"2009","unstructured":"Yeo W, Chan TC, Leung NW et al (2009) Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 27:605\u2013611","journal-title":"J Clin Oncol"},{"key":"2447_CR87","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/blood-2008-10-163493","volume":"113","author":"R Liang","year":"2009","unstructured":"Liang R (2009) How I, treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 113:3147\u20133153","journal-title":"Blood"},{"key":"2447_CR88","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1200\/JCO.2012.48.5938","volume":"31","author":"YH Huang","year":"2013","unstructured":"Huang YH, Hsiao LT, Hong YC et al (2013) Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol Off J Am Soc Clin Oncol 31:2765\u20132772","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2447_CR89","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.leukres.2014.11.015","volume":"39","author":"TT Chen","year":"2015","unstructured":"Chen TT, Chiu CF, Yang TY et al (2015) Hepatitis C infection is associated with hepatic toxicity but does not compromise the survival of patients with diffuse large B cell lymphoma treated with rituximab-based chemotherapy. Leuk Res 39:151\u2013156","journal-title":"Leuk Res"},{"key":"2447_CR90","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.4254\/wjh.v7.i10.1377","volume":"7","author":"HC Li","year":"2015","unstructured":"Li HC, Lo SY (2015) Hepatitis C virus: virology, diagnosis and treatment. World J Hepatol 7:1377\u20131389","journal-title":"World J Hepatol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-015-2447-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2447-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2447-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T14:43:12Z","timestamp":1652884992000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-015-2447-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,21]]},"references-count":90,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["2447"],"URL":"https:\/\/doi.org\/10.1007\/s00277-015-2447-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,21]]}}}